Dorin Toader

A Biparatopic HER2-Targeting Antibody-Drug Conjugate Induces Tumor Regression in Primary Models Refractory to or Ineligible for HER2-Targeted Therapy

John Y. Li, Samuel R. Perry, Vanessa Muniz‐Medina et al. · Cancer Cell · 2016 · 390 citations · Full text

Medicine, Oncology, Pharmacology +14

Mechanism and <i>In Vitro</i> Pharmacology of TAK1 Inhibition by (5<i>Z</i>)-7-Oxozeaenol

Jiaquan Wu, Francoise Powell, Nicholas Larsen et al. · ACS Chemical Biology · 2012 · 142 citations

Medicine, Oncology, Pharmacology +13

Structure-based design of protein tyrosine phosphatase-1B inhibitors

Emma Black, J. Breed, Alexander L. Breeze et al. · Bioorganic & Medicinal Chemistry Letters · 2005 · 75 citations · Full text

Life Sciences, Biochemistry, Medicinal Chemistry +14

Tumor cell-directed STING agonist antibody-drug conjugates induce type III interferons and anti-tumor innate immune responses

Naniye Malli Cetinbas, Travis Monnell, Jahna Soomer-James et al. · Nature Communications · 2024 · 72 citations · Full text

Life Sciences, Immunology, Oncology +17

Discovery of Checkpoint Kinase Inhibitor (<i>S</i>)-5-(3-Fluorophenyl)-<i>N</i>-(piperidin-3-yl)-3-ureidothiophene-2-carboxamide (AZD7762) by Structure-Based Design and Optimization of Thiophenecarboxamide Ureas

Vibha Oza, Susan Ashwell, Lynsie Almeida et al. · Journal of Medicinal Chemistry · 2012 · 70 citations · Full text

Life Sciences, Medicinal Chemistry, Pharmacology +16